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Introduction. Current therapeutic regimens with ﬁrst-line antitubercular agents are associated to a high rate of adverse eﬀects
which could cause pronounced changes in collagen’s contents and structure. Investigation of these changes is very important for
optimization of antitubercular therapy and minimization of treatment-caused harm. The aim of present paper was to investigate
potential eﬀect of pyrazinamide on male rats’ cartilage type II collagen amino acid composition. Materials and Methods. Wistar
albinomalerats(160–200gb.w.)weredividedintothreegroups:I—receivedpyrazinamideperosatadoseof1000mg/kgb.w./day;
II—at a dose of 2000mg/kgb.w./day, in both groups it was given for 60 days; III—control. After 60 days of the experiment, rats
of the experimental (groups I and II) and control groups were sacriﬁced and the amino acids contents of male rat cartilage type
II collagens were determined using amino acid analyzer. Results and Discussion. The study of pyrazinamide eﬀects (administered
in diﬀerent doses) on rat cartilage type II collagen amino acid contents demonstrated presence of dose-dependent pyrazinamide-
mediated quantitative and qualitative changes in these rat extracellular matrix proteins in comparison with control.
1.Introduction
There has been resurgence in tuberculosis worldwide. Ap-
proximately 2 billion people have latent infection, 8 million
would develop active tuberculosis annually, and 2-3 mil-
lion would die due to tuberculosis. With this resurgence,
cases with extrapulmonary tuberculosis have also shown an
increase. Approximately 10-11% of extrapulmonary tuber-
culosis involves joints and bones, which is approximately 1–
3% of all tuberculosis cases. The global prevalence of latent
joint and bone tuberculosis is approximately 19–38 million
cases [1].
Collagens are major structural proteins of the extracel-
lular matrix, joints, and bones and their correct structure is
crucial for the proper functioning of locomotor apparatus.
Both tuberculosis per se and its chemotherapy with antitu-
bercular drugs could cause pronounced changes in collagen’s
contents and structure [1, 2]. Investigation of these changes
is very important for improving ﬁrst-line antitubercular
therapy and minimization of its adverse eﬀects.
Previously we have demonstrated putative changes in rat
bone and skin type I collagens amino acid contents with
using diﬀerent doses of pyrazinamide [2, 3]. Type II collagen
has been classically recognized as the major collagenous
component of cartilage.
The aim of present study was to investigate potential
eﬀect of pyrazinamide on male rats cartilage type II collagen
amino acid composition.
2.MaterialsandMethods
Cartilage type II collagens were extracted and puriﬁed
according to Trelstad et al. [4]. All procedures were carried
out at 4◦C. Cartilages (20g) were grinded. Extraction of
proteoglycans was carried out by 100mL 2M MgCl2,0 . 0 5M
Tris (pH 7.6) during 3 days. Extract was decanted. Cartilages
were washed by distilled water (3 times). Collagen was
extracted by 100mL 0.1M acetic acid (pH 2.5) with pepsin.
Pepsin (20mg/g of tissue) was added into this solution
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Table 1: Male rats cartilage type II collagen amino acid contents in control and with pyrazinamide administration at doses 1000mg/kg and
2000mg/kg of body weight (M ± m, n = 5, residues/1000 residues).
Amino acid Control (norm) Pyrazinamide 1000mg/kg Pyrazinamide 2000mg/kg
Hydroxylysine 5.60 ±1.20 4.20 ±0.80 3.50 ±0.40
Lysine 29.9 ±1.80 31.80 ±2.70 33.30 ±2.50
Histidine 8.30 ±1.20 7.10 ±1.30 5.60 ±0.30
Arginine 53.83 ±3.35 53.00 ±5.80 39.90 ±3.00∗#
Hydroxyproline 95.80 ±2.70 91.70 ±4.70 85.90 ±2.90
Aspartic acid 53.50 ±5.10 62.30 ±6.40 72.10 ±10.60
Threonine 29.80 ±6.60 29.20 ±1.30 33.70 ±2.10
Serine 34.00 ±1.98 49.80 ±1.60∗ 56.30 ±2.30∗#
Glutamic acid 88.10 ±3.47 115.40 ±6.30∗ 110.80 ±12.20∗
Proline 91.70 ±1.60 91.20 ±4.10 86.10 ±3.70
Glycine 310.20 ±7.70 282.10 ±9.90 294.00 ±6.40
Alanine 105.62 ±2.78 92.60 ±1.80∗ 72.10 ±5.50∗#
Valine 24.80 ±1.89 16.70 ±3.60∗ 32.90 ±1.57∗#
Methionine 7.60 ±1.50 3.80 ±1.00 2.70 ±0.70
Isoleucine 13.35 ±0.79 8.30 ±0.80∗ 10.60 ±1.80
Leucine 23.43 ±1.85 34.30 ±2.00∗ 32.90 ±1.00∗
Tyrosine 7.30 ±0.80 6.80 ±0.30 7.50 ±0.50
Phenylalanine 18.80 ±0.80 20.80 ±2.30 20.60 ±2.10
M ± m: mean ± mean standard error.
∗P<0.05 statistically signiﬁcant in comparison with control.
#P<0.05 statistically signiﬁcant pyrazinamide, 1000mg/kg group versus pyrazinamide, 2000mg/kg group.
After that for pepsin inactivation pH in each mixture
was neutralized by addition of powdered crystalline Tris
(to pH 7.6). Solutions were centrifuged: 35000g, 40min,
4◦C. Pellets were discarded and supernatants were used for
further collagen types fractionation. Fractionation of pure
type II collagens was carried out by growing concentrations
of NaCl according to method [4]. Protein fraction from
pellet which was formed at 4.4M NaCl concentration
contained type II collagen. Fractions were separated by
centrifugation (65000g, 60min, at 4◦C). Obtained pellets
were recrystallized (3 times) by dialysis (against 15% KCl in
0.02MNaHPO4 at4◦C)andcentrifugation(65000g,60min,
at 4◦C) [5]. Collagen preparations purity was controlled
electrophoretically [6].
Collagenfractionswerehydrolyzed:24h,6NHCl,105◦C
[7]. Their amino acid compositions were analyzed by ion
exchange chromatography on the amino acid analyzer AAA-
881 (Czech Republic).
In statistical processing of experimental data mean of
corresponding parameter (for each animal) was used as
independent variable. The obtained data were calculated by
one-way analysis of variance (ANOVA). Data were compared
using Tukey test. Diﬀerences were considered to be statisti-
cally signiﬁcant at P<0.05.
3. Results andDiscussion
Changes in male rat cartilage type II collagen amino acid
contents induced by pyrazinamide were profound as com-
pared to control (Table 1). Statistically signiﬁcant changes
were registered in cartilage collagen with pyrazinamide
administration at dose 1000mg/kg for 6 amino acids and at
dose 2000mg/kg for 6 amino acids.
Cartilage type II collagen of male rats with pyrazinamide
at dose 1000mg/kg contains lower contents of alanine
(−12.3%) and isoleucine (−37.8%) simultaneously with
higher contents of serine (+46.5%), glutamic acid (+31.0%),
and leucine (+46.6%). Collagen of rats with pyrazinamide
at dose 2000mg/kg contains lower contents of arginine
(−25.9%) and alanine (−31.7%) simultaneously with higher
contents of serine (+65.6%), valine (+32.7%), and leucine
(+40.6%). For the majority of amino acids pyrazinamide
eﬀects were dose dependent.
Our experiments demonstrated presence of qualitative
changes in male rats’ cartilage type II collagens with
pyrazinamide (in comparison with norm) (Table 1). With
pyrazinamide administration possibly could be formed car-
tilage type II collagen molecules with changed surface charge
(changes in number of arginine, serine, and glutamic acid
residues), rigidity (changes in quantity of alanine, valine,
isoleucine residues), number of speciﬁc loci responsible for
cell adhesion, interaction with chaperons, and procollagen
processing to collagen (changes in arginine residues) [8–
14]. Such collagen molecules changes could hence aﬀect the
properties of connective tissues, mineralisation processes,
and calcium metabolism.
Comparativeanalysisofpresentresultswithourprevious
data on skin and bone type I collagens demonstrated
analogous character of changes in regard to contents of
serine, glutamic acid, alanine, valine, and leucine residues
[2, 3]. This could be the evidence of existence some general
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and structure. Moreover, having compared these data with
our previous experiments, we found out analogous character
of these changes in regard to changes of free serine, glutamic
acid, alanine, valine, and leucine contents in liver, kidney,
lung and spleen pools with diﬀerent doses of pyrazinamide
[8]. Thus adverse eﬀects of pyrazinamide (this widely
used antitubercular drug) are much more serious and
more profound than it was considered earlier. Among this
pyrazinamide treatment could cause qualitative changes in
nucleic acid molecules, change their length, and structure
[9].
We can suppose that such changes could be caused
by pyrazinamide via its inﬂuence on nucleic acids (coding
information for this proteins synthesis) as it was mentioned
previously [2, 9, 10]. In our previous experiments we
demonstrated epigenetic changes induced by pyrazinamide
treatment, pyrazinamide-mediated alterations in male rats
DNA fragmentation processes, bone type I collagen amino
acid composition, spermatogenesis indices, reproductive
capability, and posterity antenatal and postnatal develop-
ment. Besides these, on changes in collagen metabolism
and structure pathologic changes in amino acid metabolism
could also be aﬀected [8]. And at last, due to collagen
genes polymorphism [11–14], collagen structures contain
in norm 4 diﬀerent α-chains of the same type in diﬀerent
concentrations. Pathology [14] changed concentrations in
which these 4 diﬀerent α-chains of the same type of
collagen are present in connective tissue structures. Possibly
pyrazinamide-caused disturbances in amino acid composi-
tions in our experiments could be a result of such changes in
transcription rates of genes coding diﬀerent α-chains from
the same type collagen superfamily as it was previously
demonstrated for other pathology [14].
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